Resveratrol for Metabolic and Cardiovascular Health: A Systematic Evidence Review
Does resveratrol improve metabolic and cardiovascular health markers in adults?
Evidence supports: Fasting Insulin, Insulin Resistance, Glycated Hemoglobin (HbA1c), Fasting Plasma Glucose +10 more
No clear effect: Waist-to-Hip Ratio / Central-to-Hip Fat Distribution, Adiponectin
Mixed results: Total Cholesterol, Low-Density Lipoprotein Cholesterol
Early data: Postprandial Glucose Response, Total Cholesterol to HDL Cholesterol Ratio, Body Weight +1 more
Abstract
Resveratrol appears to help some metabolic markers, but its benefits are selective and usually modest rather than transformative.1312 The clearest pattern is in glucose regulation through insulin handling: the current analysis suggests better insulin resistance and slightly lower fasting insulin, with HbA1c also moving in a favorable direction.131012 That matters because HbA1c reflects average blood sugar over roughly 2 to 3 months, and even small improvements can signal better metabolic control, although the average drop here, about 0.2 percentage points on a scale where 0.5 points is usually considered clinically meaningful, is more likely to show up on lab work than in how someone feels day to day.312
Resveratrol looks less convincing outside glycemic control.5614 Triglycerides decline a little in the pooled evidence, but the average reduction, about 8 mg/dL, is far below the roughly 50 mg/dL change usually considered clearly meaningful.115 Cholesterol results are mixed: total cholesterol and LDL sometimes improve, sometimes do not, and HDL changes are small and inconsistent.3514 Blood pressure shows a similar pattern. Systolic pressure may fall by about 5 mmHg on average, which is close to a clinically worthwhile change, but the effect is not stable across studies; diastolic pressure is weaker and often null.1316
Resveratrol does not look like a weight-loss supplement.3412 Body weight is essentially unchanged overall, BMI shifts are tiny, and any body fat effects seem too small to reliably notice without formal measurement.912 Liver fat is one of the more interesting early signals, but the evidence is still sparse and based on small studies.81213
Overall, the evidence reviewed here suggests resveratrol may modestly improve metabolic health, especially in adults with worse baseline metabolic dysfunction, but it does not deliver broad or dependable cardiometabolic improvement across all populations.31014
In Plain Language
Resveratrol probably helps some blood-test markers of metabolism, especially insulin resistance and long-term blood sugar, but the average benefit is small. It may also slightly lower triglycerides and the top number of blood pressure in some people. It does not look like a good choice for weight loss, and it does not reliably improve cholesterol overall.
The people most likely to benefit seem to be those with worse metabolic health at baseline, such as type 2 diabetes or metabolic syndrome. In healthier overweight adults, results are often weak or absent.
If you are considering resveratrol, think of it as a possible small add-on for glucose control, not a broad heart-health or fat-loss supplement.
Introduction
Resveratrol has attracted interest because it sits at the intersection of metabolism, vascular biology, and aging research.145 The practical question is simpler than the hype: does taking it actually improve common metabolic and cardiovascular markers in adults?
The current evidence points to a narrow yes, not a sweeping one.1312 Resveratrol seems more likely to improve how the body handles insulin than to cause major changes in weight, cholesterol, or overall cardiometabolic risk.31012 That distinction matters. A supplement can shift a few lab markers without functioning like a broad lifestyle replacement, and that is largely the pattern here.5614
Another important theme is that population matters.3810 Trials in type 2 diabetes, metabolic syndrome, and other metabolically impaired groups tend to show the largest gains, while healthier overweight adults often show little or no benefit.31012 Dose does not cleanly explain the difference. Positive and null trials appear across the full studied range, from 150 mg/day to 3 g/day, so more is not obviously better.12512
This review focuses on adult human trials and asks a practical question: where does resveratrol actually help, where does it fail, and how much of the apparent benefit is large enough to matter outside a spreadsheet?131214
Evidence 1 of 5
Glucose Control Improves More Reliably Than It Dramatically Changes
Resveratrol shows its most credible metabolic signal in insulin handling, not in large glucose drops.131012 In the current analysis, insulin resistance improves modestly overall, with a pooled effect size of 0.49 and a confidence interval of 0.08 to 0.89. A confidence interval is the range of effects still reasonably compatible with the data. In native terms, that works out to about a 0.4-point drop in HOMA-IR, just under the 0.5-point change usually considered clearly meaningful.13 Fasting insulin also leans favorable, by about 1.8 µU/mL on average, which is real but still smaller than the roughly 3 µU/mL change likely to matter clinically.1312
HbA1c also suggests benefit, but the average improvement is easier to measure than to feel.3512 The pooled effect favors resveratrol, and the native-unit change is about 0.2 percentage points. Because HbA1c reflects longer-term glucose exposure, that is directionally encouraging, but it falls short of the 0.5-point drop usually treated as clinically meaningful.312 The strongest single signal came from adults with type 2 diabetes taking 1 g/day for 45 days, where HbA1c fell by 1.2 percentage points while placebo stayed flat, alongside large drops in fasting glucose, insulin, and HOMA-IR.3 By contrast, overweight adults taking 150 mg/day for 6 months saw only a small HbA1c difference, and several higher-dose studies in obese or prediabetic adults found no clear glucose benefit at all.2512
Fasting glucose is where the evidence gets noticeably less stable.131112 The pooled estimate leans positive, but the confidence interval crosses no effect, which means the average result is compatible with anything from little benefit to a modest reduction. The native-unit average, about 5.6 mg/dL lower fasting glucose, is again below the 9 mg/dL threshold usually considered clearly meaningful.112 Some trials did find larger changes, especially in type 2 diabetes, where fasting glucose fell by about 35 mg/dL over 45 days.3 Others found essentially no change, including longer studies in overweight adults and postmenopausal women.1112
Post-meal glucose control remains promising but preliminary.710 Only two studies feed this outcome, and they disagree in strength. In men with metabolic syndrome taking about 2.1 g/day for 30 days, 2-hour glucose after an oral glucose tolerance test fell from 172 to 139 mg/dL, which is the kind of shift that could matter metabolically.10 But a 4-week crossover trial in overweight adults taking 150 mg/day found no change in meal-related glucose exposure.7 The pooled signal is therefore better read as an early lead than an established effect.
Variation between studies is a central part of the story, not a side note.23512 Heterogeneity, often reported as I-squared, describes how much trial results differ beyond what would be expected by chance alone. Here it is high, around 75 to 89% for several glycemic outcomes, meaning the average result hides major differences across populations and trial designs. The prediction intervals also cross no effect, which means benefit is likely real on average but may disappear in some new settings.312
What this means
Resveratrol most likely offers small improvements in insulin sensitivity and long-term glucose control, with the biggest gains showing up in people who already have metabolic dysfunction. It is not a dependable glucose-lowering supplement for everyone, and the average benefit is usually modest enough to matter more on blood tests than in symptoms.
Fasting Insulin
Proven benefit Strong · 95Proven modest benefit
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 15 papers, majority low risk |
| Inconsistency | Serious | I²=79% (> 75%) |
| Imprecision | No concern | N=5947 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.001, funnel asymmetry detected (k=12) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | High | |
Insulin Resistance
Proven benefit Strong · 75Proven modest benefit
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 15 papers, majority low risk |
| Inconsistency | Serious | I²=89% (> 75%) |
| Imprecision | No concern | N=3068 meets OIS=400 |
| Publication bias | No concern | Egger's p=0.215, no asymmetry detected (k=12) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Moderate | |
Glycated Hemoglobin (HbA1c)
Proven benefit Strong · 94Proven but unnoticeable
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 11 papers, majority low risk |
| Inconsistency | Serious | I²=76% (> 75%) |
| Imprecision | No concern | N=5576 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.001, funnel asymmetry detected (k=11) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | High | |
Fasting Plasma Glucose
Likely helps Good · 51Likely modest benefit
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 18 papers, majority low risk |
| Inconsistency | Serious | I²=75% (> 50%) |
| Imprecision | No concern | N=7590 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.000, funnel asymmetry detected (k=16) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
Postprandial Glucose Response
Early data Limited · 42Barely detectable
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 2 papers, majority low risk |
| Inconsistency | No concern | no concerns (no data) |
| Imprecision | Very serious | N=118 far below OIS=400 |
| Publication bias | No concern | k=2 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
Evidence 2 of 5
Triglycerides Move, Cholesterol Fractions Mostly Do Not
Resveratrol appears to help triglycerides a little, but it does not consistently improve the rest of the lipid panel.131415 The triglyceride signal is statistically solid in the pooled data, with a pooled effect size of 0.35 and a confidence interval of 0.08 to 0.62. Yet the native-unit change is only about 8 mg/dL, far below the roughly 50 mg/dL shift usually considered clearly meaningful.115 That means the effect is probably real, but modest enough that many people would see only a small lab change. The standout exception was older adults with type 2 diabetes taking 1 g/day for 6 months, where triglycerides fell from 170 to 147 mg/dL.15
Total cholesterol does not show a dependable benefit.3121416 The overall estimate trends favorable, but the result misses conventional statistical significance and remains clinically small, about 8.5 mg/dL on average on a measure where a 20 mg/dL change is a more meaningful benchmark.12 More importantly, the studies do not tell one clear story. Some move in the right direction, others are flat, and the pooled prediction interval crosses no effect, meaning a future trial could easily find no meaningful change.31416
LDL cholesterol is even more inconsistent than total cholesterol.3514 The pooled estimate barely favors treatment, but heterogeneity is extreme, with I-squared at 92.9%. That means the studies disagree sharply, not just in size but in practical interpretation. One diabetes trial reported an LDL drop of about 11 mg/dL with resveratrol while placebo rose by about 9 mg/dL over 45 days.3 But dyslipidemia and older-adult trials did not reproduce that pattern, and the average modeled LDL reduction, about 5.7 mg/dL, still falls well short of the 15 mg/dL change that would usually feel clinically persuasive.514
HDL cholesterol remains a faint signal rather than a reliable win.3516 One positive diabetes trial found HDL rose by about 4.8 mg/dL over 45 days, which comes close to the 5 mg/dL change often considered meaningful.3 But most other trials were null, and the pooled estimate suggests only about a 1.1 mg/dL average rise overall.516 That is the kind of difference that may exist statistically while being easy to overinterpret clinically.
Cholesterol ratio findings are simply too thin to lean on.13 Only one small study contributes meaningfully here, and while the direction is favorable, the evidence is too sparse to treat the result as dependable.
Taken together, the lipid story is selective rather than broad.1314 Triglycerides are the most plausible target. Cholesterol fractions are mixed enough that resveratrol should not be expected to act like a general lipid-correcting supplement.
What this means
If the goal is lipid improvement, resveratrol is mostly a triglyceride supplement, and even there the average gain is small. It is not a reliable way to lower LDL, raise HDL, or broadly normalize cholesterol.
Triglycerides
Proven benefit Strong · 95Proven but unnoticeable
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 20 papers, majority low risk |
| Inconsistency | Serious | I²=79% (> 75%) |
| Imprecision | No concern | N=9722 meets OIS=400 |
| Publication bias | No concern | Egger's p=0.183, no asymmetry detected (k=19) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | High | |
Total Cholesterol
Mixed results Strong · 95Studies contradict
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 18 papers, majority low risk |
| Inconsistency | No concern | no concerns (I²=47%, consistency=72%, PI crosses null) |
| Imprecision | No concern | N=8561 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.000, funnel asymmetry detected (k=16) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | High | |
Low-Density Lipoprotein Cholesterol
Mixed results Good · 50Studies contradict
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 15 papers, majority low risk |
| Inconsistency | Serious | I²=93% (> 75%) |
| Imprecision | No concern | N=8469 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.000, funnel asymmetry detected (k=14) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
HDL Cholesterol
Likely helps Good · 51Likely real but unnoticeable
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 17 papers, majority low risk |
| Inconsistency | Serious | I²=71% (> 50%) |
| Imprecision | No concern | N=7083 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.000, funnel asymmetry detected (k=12) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
Total Cholesterol to HDL Cholesterol Ratio
Early data Very early · 37Faint early signal
Single study: A 2022, d=0.23 (n=35+36)
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 1 papers, majority low risk |
| Inconsistency | No concern | single study, inconsistency N/A |
| Imprecision | Very serious | single small study (N=71) |
| Publication bias | No concern | k=1 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
Evidence 3 of 5
Vascular Risk Signals Are Present but Uneven
Resveratrol may improve vascular risk markers, but the benefits are narrower than the hype suggests.1316 The most useful signal is systolic blood pressure. In pooled analysis it favors resveratrol with an effect size of 0.54 and a confidence interval of 0.05 to 1.04, which translates to about a 4.8 mmHg reduction. That is close to the 5 mmHg drop often considered clinically worthwhile.13 In practical terms, this is one of the few resveratrol outcomes that approaches a change large enough to matter if it holds.
The problem is that systolic blood pressure does not improve consistently in every setting.1251016 Two early trials found striking short-term reductions, including about 6 mmHg in obese men taking 150 mg/day for 30 days and about 7.6 mmHg in adults with type 2 diabetes taking 1 g/day for 45 days.13 But several other studies, including trials using much higher doses, found little or no benefit.251016 Heterogeneity is moderate, with I-squared near 59%, and the prediction interval crosses no effect, meaning the average benefit may be real while still failing to repeat in some new populations.
Diastolic pressure does not look nearly as convincing.13516 The pooled estimate is small and the confidence interval crosses no effect. In native terms, the average change is about 1.9 mmHg, well below the 5 mmHg threshold that would usually count as clearly meaningful.13 Even trials that improved systolic pressure often left diastolic pressure largely unchanged.13
Homocysteine is a more interesting signal than most people would expect, but it is not yet a fully mature one.11 Homocysteine is a blood marker associated with vascular risk, and the available evidence leans favorable with a moderate-sized median effect. Still, it rests on limited direct evidence in this review, so it is better treated as supportive than decisive.
Overall, the vascular pattern suggests a modest blood pressure effect concentrated in systolic pressure, plus a possible favorable shift in some biochemical risk markers.1311 That is useful, but it falls short of a broad or predictable cardiovascular benefit.
What this means
Resveratrol may modestly lower top-number blood pressure in some adults, especially those with worse metabolic health, but the effect is not reliable enough to count on. Bottom-number pressure and broader vascular risk markers are less settled.
Homocysteine
Likely helps Strong · 72Likely modest benefit
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 1 papers, majority low risk |
| Inconsistency | No concern | single study, inconsistency N/A |
| Imprecision | Serious | single study (N=2551), unreplicated |
| Publication bias | No concern | k=1 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Moderate | |
Systolic Blood Pressure
Likely helps Good · 50Likely modest benefit
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 13 papers, majority low risk |
| Inconsistency | Serious | I²=59% (> 50%) |
| Imprecision | No concern | N=3811 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.002, funnel asymmetry detected (k=10) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
Diastolic Blood Pressure
Likely helps Good · 50Likely real but unnoticeable
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 13 papers, majority low risk |
| Inconsistency | Serious | I²=84% (> 75%) |
| Imprecision | No concern | N=3977 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.000, funnel asymmetry detected (k=10) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
Evidence 4 of 5
The Scale Barely Changes, Though Fat-Specific Measures May Shift Slightly
Resveratrol does not look like a meaningful weight-loss intervention.3412 Body weight is essentially unchanged overall, with a pooled effect near zero and a prediction interval that comfortably includes both small loss and no effect. In native units, the average change is only about 0.2 kg on a measure where roughly 4 kg would be a clinically meaningful shift.34 That is why the response rate estimate is so low, only about 1 in 85 people reaching a meaningful result.
BMI changes are statistically detectable in some analyses but too small to matter much on their own.39 The average reduction is about 0.2 kg/m², compared with a rough meaningful-change threshold of 1.5 kg/m².9 One 12-week NAFLD trial found a small but significant BMI benefit of 0.31 kg/m², but that is still well below the size usually associated with a noticeable change in body shape or health status.9
Body fat measures hint that resveratrol may slightly alter composition even when body weight stays flat.12 Signals for central adiposity, percent body fat, and total fat mass trend favorable, and percent body fat shows the most interesting effect among them. But the absolute shifts are small, and most would require DXA or careful anthropometry to detect rather than being obvious in the mirror or on the scale.12 That makes these findings biologically interesting, but not yet practically impressive.
Waist-to-hip ratio does not appear to budge at all.12 This is one of the cleaner null results in the review and argues against any major redistribution of body fat.
The overall body-composition story is that resveratrol may nudge fat biology without producing meaningful weight loss.3912 That fits the broader pattern of the review: small metabolic remodeling, limited outward change.
What this means
Resveratrol should not be chosen for weight loss. If it changes body composition at all, the effect is subtle, slow, and unlikely to be noticeable without formal testing.
Body Mass Index
Proven benefit Strong · 82Proven but unnoticeable
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 10 papers, majority low risk |
| Inconsistency | No concern | no concerns (I²=0%, consistency=100%, PI does not cross null) |
| Imprecision | No concern | N=11503 meets OIS=400 |
| Publication bias | No concern | k=9 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Moderate | |
Body Weight
Early data Limited · 49Barely detectable
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 11 papers, majority low risk |
| Inconsistency | Serious | I²=72% (> 50%) |
| Imprecision | No concern | N=10605 meets OIS=400 |
| Publication bias | Serious | Egger's p=0.000, funnel asymmetry detected (k=10) |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
Central Adiposity
Likely helps Strong · 72Likely real but unnoticeable
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 4 papers, majority low risk |
| Inconsistency | Serious | I²=90% (> 75%) |
| Imprecision | No concern | N=6021 meets OIS=400 |
| Publication bias | No concern | k=3 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Moderate | |
Percent Body Fat
Likely helps Strong · 74Likely modest benefit
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 2 papers, majority low risk |
| Inconsistency | Serious | I²=80% (> 75%) |
| Imprecision | No concern | N=1294 meets OIS=400 |
| Publication bias | No concern | k=2 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Moderate | |
Total Body Fat Mass
Proven benefit Strong · 92Proven but unnoticeable
Single study: M 2020, d=0.19 (n=20+21)
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 3 papers, majority low risk |
| Inconsistency | No concern | no concerns (I²=44%, consistency=100%, PI crosses null) |
| Imprecision | No concern | N=3967 meets OIS=400 |
| Publication bias | No concern | k=3 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | High | |
Waist-to-Hip Ratio / Central-to-Hip Fat Distribution
Likely no effect Strong · 68Probably doesn't help
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 1 papers, majority low risk |
| Inconsistency | No concern | single study, inconsistency N/A |
| Imprecision | Serious | single study (N=459), unreplicated |
| Publication bias | No concern | k=1 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Moderate | |
Evidence 5 of 5
Biomarker and Liver Findings Suggest Targeted Metabolic Remodeling
Mechanistic markers suggest resveratrol may tweak metabolic signaling without producing uniform downstream benefits.1512 Leptin falls slightly in the available evidence, and one early obese-male crossover trial found levels dropped from 14.28 to 12.91 ng/mL after 30 days of 150 mg/day.1 Because leptin reflects adipose signaling and energy balance, that points toward a real biological effect. But the average effect is small, so it should be read as a pathway signal, not a clinical endpoint.
Adiponectin is the opposite story: resveratrol does not appear to help.15 The pooled result is tightly null, with no sign of consistent improvement and no meaningful heterogeneity. This is useful negative evidence. It suggests resveratrol's metabolic effects are selective rather than globally beneficial across every adipokine pathway.
Liver fat is one of the more clinically interesting possibilities, but the evidence remains early.81213 The pooled effect leans favorable and the estimated magnitude is large enough to potentially matter, unlike many other outcomes here. But only two small studies contribute substantially, totaling just over 100 participants, and neither provides the kind of replication needed for a confident conclusion. One 6-month overweight-adult trial using 150 mg/day found no significant change in intrahepatic lipid by proton MR spectroscopy, while another small evidence stream suggests a more favorable direction overall.81213
This combination, lower leptin, no adiponectin change, and a tentative liver-fat signal, fits the idea that resveratrol may modify specific metabolic pathways rather than act as a broad-spectrum metabolic reset.112 That is scientifically plausible, but still not strong enough to promise liver benefit in routine use.
What this means
Resveratrol may influence some metabolic signaling pathways, and liver fat is a reasonable area for future research, but the current analysis does not establish a dependable liver benefit. Adiponectin, in contrast, looks like a genuine dead end.
Leptin
Proven benefit Strong · 93Proven but unnoticeable
Single study: S 2011, d=0.21 (n=11+11)
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 2 papers, majority low risk |
| Inconsistency | No concern | no concerns (I²=46%) |
| Imprecision | No concern | N=1193 meets OIS=400 |
| Publication bias | No concern | k=2 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | High | |
Adiponectin
No clear effect Strong · 92Doesn't appear to help
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 4 papers, majority low risk |
| Inconsistency | No concern | no concerns (I²=0%, PI crosses null) |
| Imprecision | No concern | N=1303 meets OIS=400 |
| Publication bias | No concern | k=4 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | High | |
Hepatic Steatosis / Liver Fat Content
Early data Limited · 44Promising early signal
▸ GRADE Assessment
| Domain | Rating | Reason |
|---|---|---|
| Risk of bias | No concern | 4 papers, majority low risk |
| Inconsistency | No concern | no concerns (no data) |
| Imprecision | Very serious | N=108 far below OIS=400 |
| Publication bias | No concern | k=2 usable (< 10), cannot assess per Cochrane 10.4 |
| Indirectness | No concern | deferred to Phase 2 (#1546) |
| Overall certainty | Low | |
Across the Evidence
The big pattern is selectivity.131214 Resveratrol helps some parts of metabolic physiology, especially insulin-related markers, without producing the broader profile people often expect from a cardiometabolic supplement. That selective pattern makes biological sense. Resveratrol has been linked to pathways involving insulin signaling, mitochondrial function, endothelial biology, and cellular stress responses, which could improve glucose handling before they meaningfully change body weight or the full lipid panel.15810
Baseline metabolic health probably explains a large share of the study-to-study disagreement.3101214 The largest effects repeatedly show up in adults with type 2 diabetes or more overt metabolic dysfunction, while healthier overweight or older adults often show weak or null results.3512 That is exactly what would be expected if resveratrol acts more like a metabolic amplifier of existing dysfunction than a universal optimizer. When baseline glucose, insulin resistance, or triglycerides are already near normal, there is simply less room to improve.
Dose is surprisingly unhelpful as an organizing principle.12512 Benefits and null results appear at low doses like 150 mg/day, intermediate doses like 500 to 1000 mg/day, and high doses above 2 g/day.1351012 That weakens the common assumption that poor results merely reflect underdosing. Bioavailability, timing, formulation, and population may matter more than raw milligrams.
Heterogeneity is one reason the literature feels more positive at first glance than it does after closer inspection.23512 Many pooled outcomes have I-squared values in the 70 to 90% range, meaning trials differ substantially in ways that are unlikely to be random. Prediction intervals often cross no effect, which means the average benefit may be real while still being unreliable in any given new trial. In plain terms, resveratrol seems to work sometimes, in some groups, for some markers, but not consistently enough to promise uniform results.
Several favorable outcomes also look stronger because of one or two unusually positive trials.1315 The 2013 diabetes study contributed outsized improvements in fasting glucose, HbA1c, insulin, blood pressure, and lipids, while an older-diabetes trial strongly influenced triglyceride results.315 Those studies may be capturing a true responder population, but they also make the average effect look larger than the typical study effect. The median study effects are usually small, which is a better guide to what most people should expect.
The deeper takeaway is that resveratrol may slightly remodel metabolic biology without creating dramatic clinical change.1812 That is why the review finds plausible improvements in insulin resistance, triglycerides, systolic blood pressure, leptin, and perhaps liver fat, alongside minimal change in body weight, adiponectin, or many cholesterol measures. The supplement looks real, but modest.
Discussion
The evidence reviewed here suggests resveratrol can modestly improve some metabolic and cardiovascular markers in adults, with the clearest support for insulin resistance, fasting insulin, HbA1c, triglycerides, and possibly systolic blood pressure.131215 That is a credible pattern, not wishful thinking. But it is also a limited one. Most benefits are small, many are inconsistent across studies, and several are more impressive statistically than clinically.351214
What is supported is a narrow metabolic effect, especially in people who start off more metabolically impaired.31015 What is not supported is the idea that resveratrol broadly improves all major cardiometabolic outcomes. Cholesterol effects remain mixed, meaningful weight loss is absent, adiponectin does not change, and liver-fat improvement is still too preliminary to state confidently.59121314
My overall confidence is moderate. It is high for the existence of at least some beneficial signal, and lower for how much any given person should expect from taking resveratrol.312 The main reason is inconsistency. Many pooled outcomes show substantial heterogeneity and prediction intervals crossing no effect, so average results do not translate cleanly into dependable individual outcomes.2512
What would change the picture is not another small short trial in a mixed population.278 The field needs larger, preregistered trials focused on clearly defined high-risk groups, using consistent formulations, longer follow-up, and clinically important endpoints rather than scattered biomarker sets. Head-to-head comparisons of low versus high dose would also help, because the current evidence does not reveal a stable best dose across the studied 150 to 3000 mg/day range.1251012
The honest bottom line is straightforward: resveratrol is not useless, but it is not a metabolic game changer either.1312 It may be worth considering as an adjunct in adults with insulin resistance or type 2 diabetes who are looking for small improvements in metabolic markers, but expectations should stay modest and focused on labs rather than obvious day-to-day change.
Methodology
We searched PubMed for studies on resveratrol and metabolic or cardiovascular health, then included controlled human trials that matched the review question. Sixteen indexed studies were included, covering 1,038 participants across populations such as type 2 diabetes, obesity, metabolic syndrome, dyslipidemia, NAFLD, hypertension, and generally healthy overweight adults.116
We read each study and recorded what it measured, how large it was, how long treatment lasted, and what it found. We assessed evidence quality with the GRADE framework and judged clinical importance against published meaningful-change thresholds for outcomes such as HbA1c, fasting glucose, triglycerides, blood pressure, BMI, and body weight.
GRADE was developed for drug trials and tends to rate nutrition and supplement evidence conservatively. It automatically downgrades observational evidence and usually upgrades only very large effects, often above a risk ratio of 2.0. That can make nutrition findings look weaker on paper than they feel in context. Our trust score is a continuous 0 to 100 judgment that also considers whether the observed change reaches a meaningful clinical threshold. So when GRADE says "low certainty" but the trust signal is stronger, that reflects a real difference between a drug-centered evidence framework and the realities of supplement research.
Every study cited here is publicly indexed on PubMed. Main limitations are clinical heterogeneity, small samples in several trials, short durations in many studies, inconsistent measurement methods, and too few studies for some endpoints.
Study Selection
Characteristics of Included Studies
| Study | Design | N | Population | Dose | Duration | RoB |
|---|---|---|---|---|---|---|
| S 2011 FT | rct | 11 | clinical | 150 mg/day for 30 days | 30 days per intervention period (30-day resveratrol vs 30-day placebo) with 4-week wash-out between crossover periods. | Some |
| M 2013 FT | rct | 24 | clinical | 1500 mg daily (500 mg three times daily for 4 weeks) | 4 weeks | Low |
| A 2013 FT | rct | 66 | clinical | 1 g/day (500 mg twice daily) for 45 days | 45 days | Low |
| R 2015 FT | rct | 119 | clinical | Titrated from 500 mg/day up to 1000 mg twice daily over 52 weeks | 52 weeks | Low |
| R 2017 FT | rct | 30 | subclinical | 2–3 g/day for 6 weeks | Two randomly assigned 6-week treatment periods (resveratrol and placebo) with a 3-week washout period between periods. | Some |
| S 2017 FT | rct | 30 | healthy | 500 mg/day for 12 weeks | 12 weeks | Some |
| S 2017 FT | rct | 50 | healthy | 150 mg daily for 4 weeks | 4 weeks (each intervention period); washout ≥ 4 weeks | Some |
| M 2018 FT | rct | 13 | subclinical | 150 mg/day for 30 days | 30 days (34 days protocol for BAT subset) | Some |
| S 2018 FT | rct | 60 | clinical | 600 mg daily for 12 weeks | 12 weeks | Low |
| J 2019 FT | rct | 31 | clinical | ~2.1 g daily (524 mg capsule x4/day total 2096 mg) | 35 days (30 days active treatment) | Low |
| J 2020 FT | rct | 146 | healthy | 150 mg daily (75 mg twice daily) for 12 months | Interim analysis at 12 months from a 24-month randomized crossover trial (first-stage results reported) | Low |
| M 2020 FT | rct | 41 | subclinical | 150 mg daily for 6 months | 6 mo | Low |
| A 2022 FT | rct | 76 | clinical | 1000 mg/day for 8 weeks | 8 weeks | Low |
| Y 2023 FT | rct | 187 | clinical | 100 mg daily for 8 weeks | 8 weeks | Some |
| B 2023 FT | rct | 124 | clinical | 1000 mg daily for 6 months | 6 months | Some |
| E 2025 FT | rct | 30 | clinical | 500 mg twice daily for 4 weeks | 4 weeks treatment - 4 weeks washout - 4 weeks treatment (cross-over); participants followed an additional 1-month after completion | High |
Sources
- 1. S 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. (2011) ↑
- 2. M 2013. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. (2013) ↑
- 3. A 2013. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. (2013) ↑
- 4. R 2015. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. (2015) ↑
- 5. R 2017. Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults. (2017) ↑
- 6. S 2017. Resveratrol Enhances Exercise-Induced Cellular and Functional Adaptations of Skeletal Muscle in Older Men and Women. (2017) ↑
- 7. S 2017. Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants. (2017) ↑
- 8. M 2018. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes. (2018) ↑
- 9. S 2018. Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. (2018) ↑
- 10. J 2019. The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: A pilot randomized, placebo-controlled clinical trial. (2019) ↑
- 11. J 2020. Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women. (2020) ↑
- 12. M 2020. No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial. (2020) ↑
- 13. A 2022. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. (2022) ↑
- 14. Y 2023. A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia. (2023) ↑
- 15. B 2023. Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes. (2023) ↑
- 16. E 2025. Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients. (2025) ↑